

Please type a plus sign (+) inside this box → ☒

PTO/SB/088 (10-96)

Approved for use through 10/31/99, OMB 0651-0031

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

Application Number	10/595,944
Filing Date	03-12-2007
First Named Inventor	HAHN
Group Art Unit	1636
Examiner Name	Kimberly A. MAKAR
Attorney Docket Number	11SAV2002/0244 - 11S - PC1

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s). volume-issue number(s), publisher, city and/or country where published.
		N. MORWOOD et al., High-efficiency gene transfer into nontransformed cells: utility for studying gene regulation and analysis of potential therapeutic targets, Arthritis Research 2002, Vol. 4, Sup. 3, pp. S215-S225
uplicate		R. POPE et al., Regulation of TNF-alpha Expression In Normal Macrophages: The Role of C/EBPbeta, Cytokines, Vol. 13, No. 8, August 2000, pp. 1171-1181
		Y.Y. WAN et al., The Survival of Antigen-Stimulated T Cells Requires NFkB-Mediated Inhibition of p73 Expression, Immunity Vol. 18, Nr. 3, March 2003,pp. 331-342

Duplicate

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are requested to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /qil/~~